1. Clinical experience with indanyl carbenicillin in urinary tract infections
- Author
-
Giamarellou E, Daikos G, Papazachos G, and Piperakis G
- Subjects
Adult ,Male ,medicine.medical_specialty ,Urinary system ,Gastroenterology ,Indanyl carbenicillin ,Internal medicine ,Humans ,Medicine ,Pseudomonas Infections ,In patient ,Pathogen ,Escherichia coli Infections ,Aged ,biology ,business.industry ,Pseudomonas ,General Medicine ,Bacteriological Cure ,Middle Aged ,Carbenicillin ,biology.organism_classification ,Surgery ,Proteus ,Acute Disease ,Chronic Disease ,Urinary Tract Infections ,Female ,Proteus Infections ,business ,medicine.drug - Abstract
SummaryA trial was carried out in 30 patients to assess the effectiveness of indanyl carbenicillin in acute or chronic urinary tract infections, many of which were complicated by a pathological urological or medical condition. In all patients, infection was due to a single species of pathogen: E. coli (19), Proteus (6), and Pseudomonas (5). Oral doses of 1 g indanyl carbenicillin were given 6-hourlyfor an average of 10 days.Results showed a clinical and bacteriological cure in 13 {43.8 %)patients. In 6 patients, although there was initial clinical improvement, the pathogen developed resistance during therapy. In 7 patients, there was super-infection with another organism. Four patients were withdrawn early in treatment because of side-effects, mainly gastrointestinal in origin. Indanyl carbenicillin proved very effective in eradicating all strains of Proteus and Pseudomonas and 12 (70.6%) of the 17 strains of E. coli in patients completing the full course of treatment.
- Published
- 1976
- Full Text
- View/download PDF